AMAG cuts hedge fund to stay with Allos
This article was originally published in Scrip
Executive Summary
AMAG Pharmaceuticals' board of directors has "unanimously" decided to oppose the unsolicited bid for the company by MSMB Capital Management as it is "not reasonably expected to result in a superior offer to the merger with Allos Therapeutics".